GET THE APP

Transrectal prostate cancer ablation by robotic High-in

Journal of Clinical & Experimental Oncology.ISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Transrectal prostate cancer ablation by robotic High-intensity focused ultrasound (HIFU) at 3 MHz: 20 years clinical experience


Christian G Chaussy

University Regensburg, Germany
: J Clin Exp Oncol

Abstract


Currently, on average, prostate cancer is diagnosed 10 years earlier and men live almost 4 years longer than 25 years ago. This means that the therapeutic necessity is more than double the time than it was then. None of the classical therapies is effective enough to cover this time frame as a monotherapy without a significant risk of aggressive recurrence during these years. Therefore, new concepts of multimodal and sequential therapies need to be introduced to cover the longer treatment period effectively to maintain the patient’s quality of life (QOL). One of these new therapeutic modalities is the treatment of prostate cancer with highintensity focused ultrasound (HIFU). High-intensity focused ultrasound (HIFU) is an emerging, noninvasive, local treatment of prostate cancer with 20 years of clinical experience, during which about 40,000 HIFU treatments have been performed worldwide. This presentation reviews the outcomes of HIFU by Ablatherm (EDAP TMS, Lyon, France), and the evolution currently underway regarding how prostate cancer is diagnosed and treated. This presentation shows the potential of HIFU to be used as local therapy for men with any stage of prostate cancer as an effective tool for salvage therapy and the possibilities for focal therapy of prostate cancer and how these additional therapeutic options can fit within the future armamentarium of a sequential multimodal therapy concept.

Biography


Christian G Chaussy was a Professor of Urology and Head of the Stone Centre from the year 1984-1986. He left this tenure position in 1986 to become Chairman of the Department of Urology Klinikum Harlaching in Munich. In 1996, he started the use of HIFU for the treatment of Localized Prostate Cancer. In 2011 he became the President of the Endourological Society and is currently holding a position of Consultant Professor at the Department of Urology, University of Regensburg. He is also a Clinical Professor of Urology at the Keck School of Medicine, USC.

Email: cgchaussy@gmail.com

Track Your Manuscript

Media Partners